Stevens M G, Olsen S C, Pugh G W, Brees D
Brucellosis Research Unit, National Animal Disease Center, Agriculture Research Service, U.S. Department of Agriculture, Ames, Iowa 50010.
Infect Immun. 1995 Jan;63(1):264-70. doi: 10.1128/iai.63.1.264-270.1995.
Immune responses and resistance to infection with Brucella abortus 2308 (S2308) were measured in mice following vaccination with B. abortus 19 (S19) or the lipopolysaccharide (LPS) O-antigen-deficient mutant, strain RB51 (SRB51). Live bacteria persisted for 8 weeks in spleens of mice vaccinated with 5 x 10(6) or 5 x 10(8) CFU of SRB51, whereas bacteria persisted for 12 weeks in mice vaccinated with 5 x 10(6) CFU of S19. Mice vaccinated with 5 x 10(6) or 5 x 10(8) CFU of SRB51 had increased resistance to infection with S2308 at 12, 16, and 20 weeks after vaccination, but the resistance was lower than that induced by vaccinating mice with 5 x 10(6) CFU of S19. Spleen cells obtained from mice vaccinated with S19 or SRB51 generally exhibited similar proliferative responses to S2308 bacteria or bacterial proteins (106 to 18 kDa) following challenge of mice with S2308 at 12, 16, or 20 weeks after vaccination. Mice vaccinated with S19 had antibody to S2308 bacteria and S2308 smooth LPS at 4, 8, and 12 weeks after vaccination. In contrast, mice vaccinated with either dose of SRB51 did not produce antibody to S2308 smooth LPS. In addition, only mice vaccinated with the highest dose of SRB51 (5 x 10(8) CFU) had antibody responses to S2308 bacteria, although the responses were lower and less persistent than those in mice vaccinated with S19. Collectively, these results indicate that SRB51-vaccinated mice have similar cell-mediated immune responses to S2308 but lower resistance to infection with S2308 compared with S19-vaccinated mice. The lower resistance in SRB51-vaccinated mice probably resulted from a combination of rapid clearance of SRB51 and an absence of antibodies to S2308 LPS.
在用流产布鲁氏菌19(S19)或脂多糖(LPS)O抗原缺陷型突变株RB51(SRB51)对小鼠进行疫苗接种后,检测了小鼠对流产布鲁氏菌2308(S2308)的免疫反应和抗感染能力。在用5×10⁶或5×10⁸CFU的SRB51接种的小鼠脾脏中,活细菌持续存在8周,而在用5×10⁶CFU的S19接种的小鼠中,细菌持续存在12周。在用5×10⁶或5×10⁸CFU的SRB51接种的小鼠在接种后12、16和20周时对S2308感染的抵抗力增强,但该抵抗力低于用5×10⁶CFU的S19接种小鼠所诱导的抵抗力。在接种后12、16或20周用S2308攻击小鼠后,从用S19或SRB51接种的小鼠获得的脾细胞对S2308细菌或细菌蛋白(106至18 kDa)通常表现出相似的增殖反应。在用S19接种的小鼠在接种后4、8和12周时具有针对S2308细菌和S2308光滑LPS的抗体。相比之下,用任一剂量的SRB51接种的小鼠均未产生针对S2308光滑LPS的抗体。此外,只有在用最高剂量的SRB51(5×10⁸CFU)接种的小鼠中对S2308细菌有抗体反应,尽管该反应比在用S19接种的小鼠中更低且持续时间更短。总体而言,这些结果表明,与用S19接种的小鼠相比,用SRB51接种的小鼠对S2308具有相似的细胞介导免疫反应,但对S2308感染的抵抗力较低。用SRB51接种的小鼠抵抗力较低可能是由于SRB51的快速清除和缺乏针对S2308 LPS的抗体共同导致的。